Aldeyra Therapeutics Inc (STU:137)
€ 4.609 -0.037 (-0.79%) Market Cap: 276.29 Mil Enterprise Value: 184.32 Mil PE Ratio: 0 PB Ratio: 3.43 GF Score: 39/100

Aldeyra Therapeutics, Inc. - Special Call Transcript

Mar 26, 2019 / 12:00PM GMT
Release Date Price: €6.22 (-2.96%)
Operator

Hello, and welcome to the Aldeyra Therapeutics, Phase III Results Conference Call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Joshua Reed, Aldeyra Therapeutics' Chief Financial Officer. Please go ahead, sir.

Joshua Reed
Aldeyra Therapeutics, Inc. - CFO

Good morning. I'm Joshua Reed, Chief Financial Officer of Aldeyra Therapeutics, and welcome to the Aldeyra Therapeutics conference call to announce top line results from the Phase III ALLEVIATE trial in allergic conjunctivitis. With me today are Dr. Todd Brady, President and Chief Executive Officer; Dr. David Clark, Chief Medical Officer; and Dave McMullin, Chief Commercial Officer.

This conference call contains forward-looking statements regarding future events and the future performance of Aldeyra. Forward-looking statements include statements regarding Aldeyra's possible or assumed future results of operations, expenses and financial position, business strategies and plans, research, development and commercial plans or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot